HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer

(2011) Edward Chu   Clinical Colorectal Cancer

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study

(2011) Andrea Sartore-Bianchi et al.   JOURNAL OF CLINICAL PATHOLOGY

KRAS and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice

(2011) C. D. Blanke et al.   ONCOLOGIST

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

(2011) A. Bertotti et al.   Cancer Discovery

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome

(2010) Jesús García-Foncillas et al.   Clinical & Translational Oncology

EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients

(2010) Y.-H. Li et al.   CLINICAL CANCER RESEARCH

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

(2009) Mario Scartozzi et al.   BMC CANCER

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

(2009) M Varella-Garcia et al.   JOURNAL OF CLINICAL PATHOLOGY

Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

(2009) F R Hirsch et al.   ONCOGENE

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

(2008) N. Personeni et al.   CLINICAL CANCER RESEARCH

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology

(2008) V Martin et al.   JOURNAL OF CLINICAL PATHOLOGY